overweight (P<0.05), while there was no effect of BMI group or ID lipid infusion on plasma 2-48 AG or OEA concentrations. Duodenal expression of IAP and ZO-1 were reduced in obese, when 49 compared with lean, individuals (P<0.05), and these changes were inversely correlated with 50 plasma AEA concentrations (P<0.05). There was a significant relationship between iAUC AEA 51 concentrations with iAUC GIP (r=0.384, P=0.005), but not iAUC GLP-1. 
INTRODUCTION

62
Obesity is associated with chronic low-grade inflammation, and a cluster of metabolic 63 disturbances, including insulin resistance and type 2 diabetes. One of the major drivers of the 64 obesity epidemic is the consumption of an energy-dense high-fat diet, which promotes hyperphagia 65 via attenuation of the gut-brain signalling mechanisms involved in the control of food intake (20).
66
In rodents, this high-fat diet-induced hyperphagia has been demonstrated to be driven by highlighted an important role of interactions between the gut microbiota and the endocannabinoid 76 system in the regulation of energy homeostasis (25).
78
The endocannabinoids, 2-arachidonyl-sn-glycerol (2-AG) and anandamide (AEA), are lipid-79 derived mediators involved in many processes, including the control of food intake (1, 10). In the 80 small intestine of rodents, 2-AG and AEA concentrations have been found to increase with fasting 81 (11), after tasting dietary fats (10), and in a model of Western diet-induced obesity (1).
82
Furthermore, they stimulate food intake by activating cannabinoid-1 (CB1) receptors (13). Human 83 obesity is associated with increased plasma and adipose tissue endocannabinoid concentrations 84 (9), and while now withdrawn from the market due to adverse psychological effects, the drug Endocannabinoids also appear to play a role in mediating the secretion of the incretin hormones, and activation of the CB1 receptor by anandamide prior to an oral glucose tolerance test inhibited 97 GIP secretion in rodents (24). In contrast, in humans, acute administration of the CB1 receptor 98 agonist, nabilone, enhanced fasting plasma GIP by ~80%, with no effect on glucose-mediated GIP 99 release, while decreasing the GLP-1 response to oral glucose (5). Therefore, it is possible that 100 changes in incretin levels observed in obesity{Verdich, 2001 #633} are mediated by altered 101 endocannabinoid levels, however, this has not been directly evaluated.
103
Endocannabinoid-related molecules, such as the fatty acid-derived mediators, n-104 acylethanolamines, in particular, OEA, have also been shown to play a role in energy homeostasis, 105 reducing energy intake (by prolonging the inter-meal interval and reducing meal frequency) via 106 activation of the nuclear receptor, peroxisome-proliferator-activated receptor-a (PPAR-a) (14, 21, 107 27). OEA is an also endogenous ligand for the fatty acid sensing receptor, GPR119, stimulating 108 GLP-1 secretion (18, 26) . Whether OEA levels are altered in human obesity is currently unclear. cannula was inserted into a forearm vein and a baseline blood sample (10 ml) was collected (t = 0 162 min). Intraduodenal infusion of 10% Intralipid ® then commenced at a rate of 2 kcal/min for 120 163 min (t = 0 -120 min), during which blood samples were collected every 15 min and placed in ice-164 chilled EDTA-treated and serum tubes, as described previously (6). 
Plasma tumour necrosis factor-α (TNF-α) and incretin hormone concentrations
217
Multiplex assays were used to determine plasma TNF-α concentrations (pg/mL) (t = 0, 10, 20, 30 assay coefficients of variation (CVs) were ≤ 10%, and inter-assay CVs were ≤ 15% for all analytes.
225
The minimum detection limits were for TNF-α: 0.7 pg/mL, GLP-1: 2.5 pg/ml, GIP: 0.6 pg/ml.
226
Data on plasma incretin hormones have been previously published (7). 
RESULTS
244
Plasma 2-AG, AEA and OEA concentrations 245 There was no effect of BMI group (P=0.77), or ID lipid infusion (P=0.33), on plasma 2-AG 246 concentrations ( Figure 1A ). There was a significant effect of group (P=0.003), but not lipid There was no effect of BMI group (P=0.7) or lipid infusion (P=0.2) on plasma concentrations of 266 TNF-α (Figure 3) . 267 Little et al. 
Relationships between variables
272
There was a significant relationship between baseline anandamide, but not 2-arachidonylglycerol 273 or oleoylethanolamine, concentrations with BMI (r=0.34, P=0.014).
275
There were inverse relationships between BMI and baseline expression of ALP-1 (r=-0.329,
276
P=0.014), occludin (r=-0.28, P=0.038) and TJP-1 (r=-0.395, P=0.003). anandamide levels were also correlated with plasma GIP, indicating that the endocannabinoid 294 system may play an important role in mediating the GIP secretion in humans.
296
Our finding of increased plasma AEA in obesity is consistent with numerous reports in both 297 animals and humans that peripheral endocannabinoid levels are increased in obesity (1, 9, 22).
298
Mean fasting plasma 2-AG levels also appeared higher in obese compared with lean and 299 overweight, however, the results were more variable between individuals and not significant.
300
Rodent studies indicate that changes in peripheral endocannabinoid concentrations are induced by suggesting an important role for these molecules in mediating the chronic low-grade inflammation 331 associated with obesity.
333
We also found an inverse relationship between plasma anandamide levels and the duodenal with reduced subsequent energy intake (23).
367
In conclusion, we have demonstrated increased plasma levels of AEA, but not 2-AG or OEA, in 
